People: Oncolytics Biotech Inc (ONCY.O)

ONCY.O on Consolidated Issue listed on NASDAQ Capital Market

1.40USD
25 Jul 2014
Price Change (% chg)

$-0.03 (-2.10%)
Prev Close
$1.43
Open
$1.43
Day's High
$1.45
Day's Low
$1.38
Volume
126,894
Avg. Vol
238,560
52-wk High
$3.50
52-wk Low
$1.20

Search Stocks

Summary

Name Age Since Current Position

Bradley Thompson

1999 Executive Chairman of the Board, President, Chief Executive Officer

Kirk Look

2012 Chief Financial Officer

Matthew Coffey

2011 Chief Operating Officer, Director

George Gill

2013 Senior Vice President - Regulatory Affairs & Chief Safety Officer

Alan Tuchman

67 2012 Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs

Mary Dillahunty

2007 Vice President - Intellectual Property

Robert Schultz

2000 Lead Independent Director

James Dinning

61 2004 Independent Director

Edwin Levy

2006 Independent Director

J. Mark Lievonen

2004 Independent Director

Wayne Pisano

2013 Independent Director

Fred Stewart

1999 Independent Director

Ger van Amersfoort

2006 Independent Director

Nick Hurst

IR Officer

Biographies

Name Description

Bradley Thompson

Dr. Bradley G. Thompson Ph.D., is an Executive Chairman of the Board, President, Chief Executive Officer of Oncolytics Biotech Inc., since April 21, 1999.

Kirk Look

Mr. Kirk J. Look CA., is Chief Financial Officer of Oncolytics Biotech Inc. effective November 12, 2012. Mr. Look has served as Oncolytics' Controller since 2003 and has been the Chief Financial Officer of Oncolytics Biotech (U.S.) Inc. since 2009. Prior to joining Oncolytics, Mr. Look held senior audit roles with Ernst & Young LLP in both North and South America over an eight year period. He holds a Bachelor of Commerce degree from the University of Calgary and is a Chartered Accountant.

Matthew Coffey

Dr. Matthew C. Coffey Ph.D., is Chief Operating Officer, Director of Oncolytics Biotech Inc. He has been Chief Operating Officer of the Corporation since December 2008. Since April 1999 to December 2008, Dr. Coffey held other senior management positions with the Company and is a co-founder of Oncolytics.

George Gill

Dr. George M. Gill M.D., is Senior Vice President - Regulatory Affairs & Chief Safety Officer of Oncolytics Biotech Inc. Dr. Gill has been a consultant in clinical research and regulatory affairs to the pharmaceutical and biotechnology industries since he retired from Ligand Pharmaceuticals in 1999. During his 38 years in the industry, he also served in senior executive positions with ICI Pharmaceuticals (now AstraZeneca), Bristol-Myers Squibb, and Hoffmann-La Roche. Dr. Gill holds a B.Sc. in chemistry from Dickinson College in Pennsylvania and an M.D. from the School of Medicine of the University of Pennsylvania in Philadelphia.

Alan Tuchman

Dr. Alan J. Tuchman M.D., MBA., is Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs of Oncolytics Biotech Inc., since September 28, 2012. Dr. Tuchman is Clinical Professor of Neurology at New York Medical College and the author of over thirty scientific papers and book chapters. He is in the private practice of Neurology in Manhattan and consults to a number of biotechnology and investment firms. He has served as a partner of Xmark Opportunity Partners and as Executive Chairman of Neurophysics, Inc. He was previously the President of the Epilepsy Society of Southern New York as well as Vice Dean for Clinical Affairs at New York Medical College. Dr. Tuchman received his MD degree from the University of Cincinnati, College of Medicine, and completed his Neurology Residency at the Mt Sinai School of Medicine. Dr. Tuchman received his MBA from Columbia University.

Mary Dillahunty

Ms. Mary Ann Dillahunty J.D., MBA., is Vice President - Intellectual Property of Oncolytics Biotech Inc., since 2007. Prior to joining Oncolytics, Ms. Dillahunty was a principal in the law firm of Fish & Richardson, a intellectual property firm in the U.S.

Robert Schultz

Mr. Robert B. Schultz is Lead Independent Director of Oncolytics Biotech Inc., since June 30, 2000. He is former Chairman and Director of Rockwater Capital Corporation, formerly McCarvill Corporation (a financial services company) from 2001 to 2007. Mr. Schultz has held a variety of senior positions, and has participated on various industry-related boards and committees including Director and Chairman of the Investment Dealers Association of Canada.

James Dinning

Mr. James F. Dinning is an Independent Director of Oncolytics Biotech Inc., since March 24, 2004. He is Chair of Western Financial Group since September 2004. Mr. Dinning was Executive Vice President of TransAlta Corporation (power generation and wholesale marketing company) from 1997 to 2004. Mr. Dinning is the Chair and Director of other public companies and not for profit entities. He is the former Chair of Export Development Canada. He will complete his four year term as Chancellor of the University of Calgary in June 2014.

Edwin Levy

Dr. Edwin Levy Ph.D., is an Independent Director of Oncolytics Biotech Inc., since May 17, 2006. He is Adjunct professor at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia since retiring from QLT Inc., in late 2002.

J. Mark Lievonen

Mr. J. Mark Lievonen is an Independent Director of Oncolytics Biotech Inc., since April 5, 2004. He is President of Sanofi Pasteur Limited, a vaccine development, manufacturing and marketing company, since October 1998. Mr. Lievonen serves on a number of industry and not-for-profit boards including Rx&D, BIOTECanada, the Ontario Institute for Cancer Research and York University, and is a past Chair of BIOTECanada and the Ontario Genomics Institute.

Wayne Pisano

Mr. Wayne Pisano is Independent Director of Oncolytics Biotech Inc., Effective from May 9, 2013. Mr. Pisano has more than 30 years of experience as a pharmaceutical industry executive and was recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. He is currently the president and CEO of VaxInnate a privately held biotech company. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor’s degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.

Fred Stewart

Mr. Fred A. Stewart Q.C., is an Independent Director of Oncolytics Biotech Inc., since August 27, 1999. He is former practising lawyer in Calgary; President of Fred Stewart & Associates Inc., consultant in commercialization of technology. Mr Stewart has served in a number of positions of corporate governance, in both private and public organizations.

Ger van Amersfoort

Mr. Ger J. van Amersfoort is an Independent Director of Oncolytics Biotech Inc., since June 15, 2006. He is President and Chief Executive Officer of Novartis Canada, a pharmaceutical company, until his retirement in 2001.

Nick Hurst

Basic Compensation

Name Fiscal Year Total

Bradley Thompson

1,076,700

Kirk Look

530,038

Matthew Coffey

706,782

George Gill

518,062

Alan Tuchman

247,794

Mary Dillahunty

275,763

Robert Schultz

--

James Dinning

--

Edwin Levy

--

J. Mark Lievonen

--

Wayne Pisano

--

Fred Stewart

--

Ger van Amersfoort

--

Nick Hurst

--
As Of 30 Dec 2013

Options Compensation

Name Options Value

Bradley Thompson

1,070,160 618,960

Kirk Look

0 0

Matthew Coffey

874,433 538,231

George Gill

197,000 54,000

Alan Tuchman

0 0

Mary Dillahunty

116,667 0

Robert Schultz

0 0

James Dinning

0 0

Edwin Levy

0 0

J. Mark Lievonen

0 0

Wayne Pisano

0 0

Fred Stewart

0 0

Ger van Amersfoort

0 0

Nick Hurst

0 0
Search Stocks